Present Title & Affiliation
- Senior Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne, Australia
- Director, Australian Cancer Survivorship Centre (ACSC), Melbourne, Australia
- Program Lead – Survivorship and Living Well After Cancer, ACSC, Melbourne, Australia
- Professorial Fellow (Professor), Sir Peter MacCallum Department of Oncology, University of Melbourne
Major Contributions to Cancer Survivorship
Professor Jefford is recognized as one of the leading global voices in cancer survivorship, shaping policy, survivorship care models, international guidelines, and training programs that have reached >10,000 clinicians worldwide. His work influenced national cancer plans, Optimal Care Pathways, survivorship resources in multiple languages, and clinical trials redefining patient-centred care after treatment.
Publications
1. Jefford M, Phillips KA, Tattersall MHN. An online educational facility for medical oncology trainees: www.vmotg.org. J Clin Oncol. 2001;19(9):2566-2569.
2. Jefford M, Maraskovsky E, Cebon J, Davis ID. The use of dendritic cells in cancer therapy. Lancet Oncol. 2001;2:343-353.
3. Jefford M. Corporatisation of Australian health (letter). Med J Aust. 2001;175(2):119.
4. Luft T, Jefford M, Luetjens P, et al. IL-1β enhances CD40L-mediated cytokine secretion by human dendritic cells. J Immunol. 2002;168:713-722.
5. Jefford M, Toner G, Smith J, et al. Phase II trial of continuous infusion carboplatin, 5-FU and radiotherapy for localized esophageal cancer. Am J Clin Oncol. 2002;25(3):277-282.
6. Jefford M, Feigen M, Somers G, et al. Squamous cell carcinoma of the seminal vesicles: case report and literature review. UroOncology. 2002;2(1):19-22.
7. Luft T, Jefford M, Luetjens P, et al. Functionally distinct DC populations induced by stimuli; PGE2 regulates their migration. Blood. 2002;100:1362-1372.
8. Jefford M, Tattersall M. Informing and involving cancer patients in their own care. Lancet Oncol. 2002;3:629-637.
9. Jefford M, Clancy J, Butler S. Quality use of medicines from hospital to community (letter). Med J Aust. 2002;177:574-575.
10. Davis ID, Jefford M, Parente P, Cebon J. Rational approaches to human cancer immunotherapy. J Leukoc Biol. 2003;73(1):3-29.
11. Jefford M, Stockler M, Tattersall M. Outcomes research: what is it and why does it matter? Intern Med J. 2003;33:110-118.
12. Jefford M, Schnurr M, Toy T, et al. Comparison of DC generated by Flt3-L in vivo vs. monocytes in vitro. Blood. 2003;102(5):1753-1763.
13. Jefford M, Zalcberg J. Palliative chemotherapy: a clinical oxymoron (letter). Lancet. 2003;362:1082.
14. Jefford M, Michael M, Rosenthal MA, et al. Cisplatin, irinotecan, and capecitabine in advanced cancers. Invest New Drugs. 2004;22:185-192.
15. Jefford M, Mileshkin L, Richards K, et al. Brief Case-Find for Depression validation. Br J Cancer. 2004;91(5):900-906.
16. Jefford M, Kiffer J, Somers G, et al. Metastatic basal cell carcinoma responsive to cisplatin/paclitaxel. ANZ J Surg. 2004;74(8):704-705.
17. Shackleton M, Davis ID, Hopkins W, et al. Imiquimod enhances melanoma peptide vaccine immunogenicity. Cancer Immun. 2004;4:9.
18. Jefford M, Zalcberg J. Systemic therapy developments in metastatic colorectal cancer. Am J Cancer. 2005;4(1):15-34.
19. Jefford M, Gibbs A, Reading D. Decision-making guide for colorectal cancer treatment. Eur J Cancer Care. 2005;14(1):16-27.
20. Jefford M, Black C, Grogan S, et al. Helpline information needs. Eur J Cancer Care. 2005;14(2):113-123.
21. Tilkeridis J, O’Connor L, Pignalosa G, Bramwell M, Jefford M. Peer support for cancer patients. Aust Fam Physician. 2005;34(4):288-289.
22. Jefford M, Kirke B, Grogan S, et al. Australia’s Cancer Helpline usage profile. Aust Fam Physician. 2005;34(5):393-394.
23. Khamly K, Jefford M, Michael M, Zalcberg J. New systemic options in colorectal cancer. Expert Opin Investig Drugs. 2005;14(6):607-628.
24. Jefford M, Savulescu J, Thomson J, et al. Discussion of high-cost drugs & patient communication. BMJ. 2005;331:1075-1077.
25. Thomson J, Schofield P, Mileshkin L, et al. Do oncologists discuss expensive drugs? Ann Oncol. 2006;17(4):702-708.
26. Milne D, Schofield P, Jefford M, et al. Communicating palliative care roles (letter). J Palliat Med. 2006;9(1):12-13.
27. Khamly K, Jefford M, Michael M, Zalcberg J. Therapy progress in GI malignancies. Expert Opin Investig Drugs. 2006;15(2):131-153.
28. Carey M, Jefford M, Schofield P, et al. Chemotherapy self-management audiovisual resource. Support Care Cancer. 2006;14(4):361-368.
29. Jefford M. Mammography interval adherence commentary (letter). Cancer. 2006;106(9):2084-2085.
30. Michael M, Mitchell PL, Hicks R, et al. Hepatic imaging vs irinotecan PK. J Clin Oncol. 2006;24(26):4228-4235.
31. Jefford M. Cancer information services collaboration. UICC World Cancer Congress Education Book. 2006:441-443.
32. Dawson SJ, Michael M, Biagi J, et al. Celecoxib + chemo-radiation in esophageal cancer. Invest New Drugs. 2007;25(2):123-129.
33. Jefford M, Jennens R, Speer T, Thursfield V. Pancreatic cancer management perceptions. Asia Pac J Clin Oncol. 2007;3(1):44-51.
34. Beardsley E, Jefford M, Mileshkin L. Lengthy consent forms reduce understanding. J Clin Oncol. 2007;(letter):e13-14.
35. Healy ML, Dawson SJ, Murray RML, et al. Octreotide-induced hypoglycemia in malignant insulinoma. Intern Med J. 2007;37:406-409.
36. Carden C, Jefford M, Rosenthal M. Cancer clinical trial information online analysis. Eur J Cancer. 2007;43(10):1574-1580.
37. Stockler MR, O’Connell R, Nowak AK, et al. Sertraline in advanced cancer without depression. Lancet Oncol. 2007;8(7):603-612.
38. Morra ME, Thomsen C, Vezina A, et al. International Cancer Information Service. J Cancer Educ. 2007;22(Suppl):S61-S69.
39. Karahalios A, Baravelli C, Carey M, et al. Transition resource development for survivorship. J Cancer Surviv. 2007;1(3):226-236.
40. Carey M, Schofield P, Jefford M, et al. Audio-visual preparation for medical procedures. Eur J Cancer Care. 2007;16(5):417-423.
41. Jefford M, Milne D, Aranda S, et al. Palliative transition communication considerations. Palliat Med. 2007;21(7):651.
42. Sutherland G, Hegarty S, White V, et al. Peer-led communication skills training. Asia Pac J Clin Oncol. 2007;3:207-213.
43. Kosmider S, Field K, Jefford M, Gibbs P. Post-treatment colorectal cancer surveillance. Intern Med J. 2008;38(6):415-421.
44. Schofield P, Jefford M, Carey M, et al. Chemotherapy educational DVD impact. Support Care Cancer. 2008;16(1):37-45.
45. Hoey L, Ieropoli S, White V, Jefford M. Peer support in cancer – systematic review. Patient Educ Couns. 2008;70(3):315-337.
46. Kosmider S, Field K, Jefford M, Gibbs P. Anticoagulation prophylaxis for central venous catheter-associated thrombosis in cancer patients: an Australian perspective. Asia Pac J Clin Oncol. 2008;4:2–5.
47. Jefford M, Karahalios E, Pollard A, Baravelli C, Carey M, Franklin J, Aranda S, Schofield P. Survivorship issues following treatment completion: results from focus groups with Australian cancer survivors and health professionals. J Cancer Surviv. 2008;2(1):20–32.
48. Jefford M, Moore R. Improvement of informed consent and the quality of consent documents. Lancet Oncol. 2008;9:485–493.
49. Jefford M, Baravelli C, Dudgeon P, Dabscheck A, Evans M, Moloney M, Schofield P. Tailored chemotherapy information faxed to general practitioners improves confidence managing side effects and satisfaction with shared care: results from a randomized controlled trial. J Clin Oncol. 2008;26(14):2272–2277.
50. Field K, Kosmider S, Jefford M, Michael M, Jennens R, Green M, Gibbs P. Chemotherapy dosing strategies in obese, elderly and thin patients: results of a nationwide survey. J Oncol Pract. 2008;4(3):108–113.
51. Sutherland G, Hoey L, White V, Jefford M, Hegarty S. How does a cancer education program impact on people with cancer and their family and friends? J Cancer Educ. 2008;23(2):126–132.
52. Field K, Kosmider S, Jefford M, Jennens R, Green M, Gibbs P. Chemotherapy treatments for metastatic colorectal cancer: is evidence-based medicine in practice? J Oncol Pract. 2008;4(6):271–276.
53. Lotfi-Jam K, Carey C, Jefford M, Schofield P, Charleson C, Aranda S. Non-pharmacological strategies for managing common chemotherapy side effects: a systematic review. J Clin Oncol. 2008;26(34):5618–5629.
54. Jefford M, Mileshkin L, Schofield P, Agalianos E, Thomson J, Zalcberg J. Discussing expensive anti-cancer drugs (letter). J Clin Oncol. 2009;27(3):476–477.
55. Au HJ, Karapetis CS, O’Callaghan CJ, Tu D, Moore MJ, Zalcberg JR, Kennecke H, Shapiro JD, Koski S, Pavlakis N, Charpentier D, Wyld D, Jefford M, Knight G, Magoski NM, Brundage MD, Jonker DJ. Health-related quality of life in advanced colorectal cancer patients treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 trial. J Clin Oncol. 2009;27(11):1822–1828.
56. Pezaro C, Jefford M. Early-stage bowel cancer: follow-up and survivorship. Aust Fam Physician. 2009;38(4):205–208.
57. Breen S, Baravelli C, Schofield P, Jefford M, Yates P, Aranda S. Anxiety and depression in the pre-chemotherapy setting: is symptom burden a predictor in the non-palliative cancer population? Med J Aust. 2009;190(7 Suppl):S99–S104.
58. Baravelli C, Krishnasamy M, Pezaro C, Schofield P, Lotfi-Jam K, Rogers M, Milne D, Aranda S, King D, Shaw B, Grogan S, Jefford M. Views of bowel cancer survivors and health care professionals regarding survivorship care plans and post-treatment follow-up. J Cancer Surviv. 2009;3(2):99–108.
59. Mileshkin L, Schofield P, Jefford M, Agalianos E, Levine M, Herschtal A, Savulescu J, Thomson J, Zalcberg J. The community wants to know about expensive anti-cancer drugs as a potential treatment option. J Clin Oncol. 2009;27(34):5830–5837.
60. Hordern A, Grainger M, Hegarty S, Jefford M, White V. Impact of a training program for oncology health professionals to enhance communication about sexuality. Asia Pac J Clin Oncol. 2009;5:270–277.
61. Jefford M. Overview: improving outcomes for cancer survivors in Australia. Cancer Forum. 2009;33(3):159–163.
62. Lotfi-Jam K, Schofield P, Jefford M. What constitutes ideal survivorship care? Cancer Forum. 2009;33(3):171–174.
63. Brennan M, Jefford M. General practitioner-based models of post-treatment follow-up. Cancer Forum. 2009;33(3):179–182.
64. Schofield P, Diggens J, Charleson C, Marigliani R, Jefford M. Effectively discussing complementary and alternative medicine in a conventional oncology setting: communication recommendations for clinicians. Patient Educ Couns. 2010;79(2):143–151.
65. Butow P, Sze M, Dugal-Beri P, Mikhail M, Eisenbruch M, Jefford M, Schofield P, Girgis A, King M, Goldstein D. From inside the bubble: migrants’ perceptions of communication with the cancer team. Support Care Cancer. 2011;19(2):281–290.
66. Jefford M, Thursfield V, Torn-Broers Y, Leong T, Guerrieri M, Speer T. Use of chemotherapy and radiotherapy in patients with pancreatic cancer in Victoria (2002–2003): a retrospective cohort study. Med J Aust. 2010;192(6):323–327.
67. Devitt B, Hatton A, Baravelli C, Schofield P, Jefford M, Mileshkin L. What should a support program for people with lung cancer look like? Differing attitudes of patients and support group facilitators. J Thorac Oncol. 2010;5(8):1227–1232.
68. Grainger M, Hegarty S, Schofield P, White V, Jefford M. Discussing the transition to palliative care: evaluation of a brief communication skills training program for oncology clinicians. Palliat Support Care. 2010;8(4):441–447.
69. Livingston PM, Craike MJ, White VM, Hordern A, Jefford M, Botti M, Lethborg C, Oldroyd J. Nurse-assisted screening and referral program for depression among survivors of colorectal cancer: a feasibility study. Med J Aust. 2010;193(5 Suppl):S83–S87.
70. Jefford M, Mileshkin L, Matthews J, Raunow H, O’Kane C, Cavicchiolo T, Brasier H, Anderson M, Reynolds J. Satisfaction with the decision to participate in cancer clinical trials is high, but understanding is a problem. Support Care Cancer. 2011;19(3):371–379.
71. Goldstein D, Gainford MG, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Fixed dose rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2011;67(3):519–525.
72. Ieropoli SC, White V, Jefford M, Akkerman D. What models of peer support do people with colorectal cancer prefer? Eur J Cancer Care (Engl). 2011;20(4):455–465.
73. Jefford M, Lotfi-Jam K, Baravelli C, Grogan S, Rogers M, Krishnasamy M, Pezaro C, Milne D, Aranda S, King D, Shaw B, Schofield P. Development and pilot testing of a comprehensive post-treatment support package for bowel cancer survivors. Cancer Nurs. 2011;34(3):E1–E10.
74. Day FL, Leong T, Ngan S, Thomas R, Jefford M, Zalcberg JR, Rischin D, McKendrick J, Milner AD, Di Iulio J, Matera A, Michael M. Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer. Br J Cancer. 2011;104(2):265–271.
75. Mellor D, Cassumbhoy M, Jefford M. Clinical guidance on the peri-operative use of targeted agents in solid tumour oncology. Asia Pac J Clin Oncol. 2011;7(2):106–113.
76. Yoong J, Jefford M, Mileshkin L. Patients’ understanding of clinical trials needs to be assessed in the context of understanding of overall goals of care (letter). Support Care Cancer. 2011;19(8):1067–1068.
77. Butow P, Lobb E, Jefford M, Goldstein D, Eisenbruch M, Girgis A, King M, Sze M, Aldridge L, Schofield P. A bridge between cultures: interpreters’ perspectives of consultations with migrant oncology patients. Support Care Cancer. 2012;20(2):235–244.
78. Aranda S, Jefford M, Yates P, Gough K, Seymour J, Francis P, Baravelli C, Breen S, Schofield P. Impact of a novel nurse-led pre-chemotherapy education intervention (ChemoEd) on distress, symptom burden, information and support needs: results from a randomised controlled trial. Ann Oncol. 2012;23(1):222–231.
79. Jefford M, Schofield P, Emery J. Improving survivorship care (letter). J Clin Oncol. 2012;30(12):1391–1392.
80. Koay K, Schofield P, Jefford M. Importance of health literacy in oncology. Asia Pac J Clin Oncol. 2012;8(1):14–23.
81. Speer T, Thursfield V, Torn-Broers Y, Jefford M. Pancreatic cancer: surgical management and outcomes after six years’ follow-up. Med J Aust. 2012;196(8):511–515.
82. Halkett GKB, Schofield P, O’Connor M, York D, Jefford M, Jiwa M, Spry N, Taylor M, Aranda S. Development and pilot testing of a radiation therapist-led educational intervention for breast cancer patients prior to commencing radiotherapy. Asia Pac J Clin Oncol. 2012;8(3):e1–e8.
83. Milne D, Aranda S, Jefford M, Schofield P. Development and validation of a tool to assess perceptions of palliative care. Psychooncology. 2013;22(4):940–946.
84. Michael M, Zalcberg J, Gibbs P, Lipton L, Gouillou M, Jefford M, McArthur G, Copeman M, Lynch K, Tebbutt N. Phase I trial of imatinib in combination with mFOLFOX6–bevacizumab in advanced colorectal cancer. Cancer Chemother Pharmacol. 2013;71(2):321–330.
85. Jefford M, Rowland J, Grunfeld E, Richards M, Maher J, Glaser A. Implementing improved post-treatment care for cancer survivors in England, with reflections from Australia, Canada and the USA. Br J Cancer. 2013;108(1):14–20.
86. Farrelly A, White V, Meiser B, Jefford M, Young MA, Ieropoli S, Winship I, Duffy J. Unmet support needs and distress among women with a BRCA1/2 mutation. Fam Cancer. 2013;12(3):509–518.
87. Coory M, White V, Johnson KS, Hill DJ, Jefford M, Harrison S, Winship I, Millar J, Giles GG. Systematic review of quality-improvement interventions directed at cancer specialists. J Clin Oncol. 2013;31(12):1583–1591.
88. Halkett GKB, O’Connor M, Aranda S, Jefford M, Shaw T, York D, Spry N, Taylor M, Schofield P. Radiation therapist-led educational intervention prior to radiotherapy: pilot RCT. Support Care Cancer. 2013;21(6):1725–1733.
89. Butow P, Aldridge LJ, Bell ML, Sze M, Eisenbruch M, Jefford M, Schofield P, Girgis A, King M, Duggal-Beri P, McGrane J, Goldstein D. Inferior health-related quality of life and psychological well-being in immigrant cancer survivors: a population-based study. Eur J Cancer. 2013;49(8):1948–1956.
90. Koay K, Schofield P, Gough K, Buchbinder R, Rischin D, Ball D, Corry J, Osborne RH, Jefford M. Suboptimal health literacy in patients with lung cancer or head and neck cancer. Support Care Cancer. 2013;21(8):2237–2245.
91. Milne D, Jefford M, Schofield P, Aranda S. Appropriate, timely referral to palliative care services: a name change won’t help (letter). J Clin Oncol. 2013;31(16):2055.
92. Butow PN, Bell M, Aldridge LJ, Sze M, Eisenbruch M, Jefford M, Schofield P, Girgis A, King M, Duggal-Beri P, McGrane J, Goldstein D. Unmet needs in immigrant cancer survivors: a cross-sectional population-based study. Support Care Cancer. 2013;21(9):2509–2520.
93. Siu L, Shapiro L, Jonker D, Karapetis C, Zalcberg J, Simes J, Couture F, Moore M, Price T, Siddiqui J, Nott L, Charpentier D, Liauw W, Sawyer M, Jefford M, Magoski N, Haydon A, Walters I, Ringash J, Tu D, O’Callaghan C. Cetuximab + brivanib alaninate vs cetuximab + placebo in metastatic KRAS WT colorectal cancer: CO.20 trial. J Clin Oncol. 2013;31(19):2477–2484.
94. Jefford M, Aranda S, Gough K, Lotfi-Jam K, Butow P, Krishnasamy M, Young J, Phipps-Nelson J, Russell L, King D, Schofield P. Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial. Trials. 2013;14:260.
95. Kiely BE, Martin AJ, Tattersall MHN, Nowak AK, Goldstein D, Wilcken NRC, Wyld DK, Abdi EA, Glasgow A, Beale PJ, Jefford M, Glare PA, Stockler MR. The median informs the message: accuracy of individualized survival scenarios based on oncologists’ estimates. J Clin Oncol. 2013;31(28):3565–3571.
96. Urban D, Lewin J, Collins IM, Mooi J, Jefford M. Rechallenge with imatinib in GIST: is more always RIGHT? (letter). Lancet Oncol. 2014;15(1):e2–e3.
97. Emery JD, Doory J, Jefford M, King M, Pirotta M, Hayne D, Martin A, Trevena L, Lim T, Constable R, Hawks C, Hyatt A, Hamid A, Violet J, Gill S, Frydenberg M, Schofield P. Protocol for the ProCare Trial: shared care for follow-up of men with prostate cancer. BMJ Open. 2014;4(3):e004972.
98. Goldstein D, Bell ML, Butow P, Sze M, Vaccaro L, Dong S, Liauw W, Hui R, Tattersall M, Ng W, Asghari R, Steer C, Vardy J, Parente P, Harris M, Karanth NV, King M, Girgis A, Eisenbruch M, Jefford M. Immigrants’ perceptions of the quality of their cancer care: an Australian comparative study. Ann Oncol. 2014;25(8):1643–1649.
99. Halkett G, O’Connor M, Aranda S, Jefford M, Spry N, Shaw T, Moorin R, Schofield P. RT Prepare Trial protocol: radiation therapist-delivered education and support for women with breast cancer. BMJ Open. 2014;4(8):e006116.
100. Michael M, Chander S, McKendrick J, Mackay J, Steel M, Hicks R, Heriot A, Leong T, Cooray P, Jefford M, Zalcberg J, Bressel M, McClure B, Ngan S. Phase II trial evaluating interdigitating FOLFOX with chemoradiotherapy in locally advanced and metastatic rectal cancer. Br J Cancer. 2014;111(10):1924–1931.
101. Jefford M, Zalcberg JR. Broken doctor–patient relationships: “why won’t they listen?” Med J Aust. 2014;201(6):347–349.
102. Jefford M, Mann GM, Nolte L, Russell L, Brennan M. Follow-up of women with early-stage breast cancer. Curr Breast Cancer Rep. 2014;6:183–192.
103. White V, Young MA, Farrelly A, Meiser B, Jefford M, Williamson E, Ieropoli S, Duffy J, Winship I. Telephone-based peer support for female BRCA1/2 carriers: randomized controlled trial. J Clin Oncol. 2014;32(36):4073–4080.
104. Russell L, Gough K, Drosdowsky A, Schofield P, Aranda S, Butow PN, Westwood JA, Krishnasamy M, Young JM, Phipps-Nelson J, King D, Jefford M. Psychological distress, quality of life, symptoms and unmet needs of colorectal cancer survivors near the end of treatment. J Cancer Surviv. 2015;9(3):462–470.
105. Sze M, Butow P, Bell M, Vaccaro L, Dong S, Eisenbruch M, Jefford M, Girgis A, King M, McGrane J, Ng W, Asghari R, Parente P, Liauw W, Goldstein D. Migrant health in cancer: outcome disparities and determinant role of migrant-specific variables. Oncologist. 2015;20(5):523–531.
106. Farrelly A, White V, Young MA, Jefford M, Ieropoli S, Duffy J, Winship I, Meiser B. Implementing a telephone-based peer support intervention for women with a BRCA1/2 mutation. Fam Cancer. 2015;14(3):373–382.
107. Loh K, Michael M, Zalcberg J, Jefford M. Views of Australian medical oncologists on mismatch repair status to assist adjuvant chemotherapy recommendations in early-stage colon cancer. Clin Colorectal Cancer. 2015;14(3):192–197.
108. Jefford M, Kinnane N, Howell P, Nolte L, Galetakis S, Mann GB, Naccarella L, Lai-Kwon J, Simons K, Avery S, Thompson K, Ashley D, Haskett M, Davies E, Whitfield K. Implementing novel models of post-treatment care for cancer survivors: enablers, challenges and recommendations. Asia Pac J Clin Oncol. 2015;11(4):319–327.
109. Eakin EG, Hayes SC, Haas MR, Reeves MM, Vardy JL, Boyle F, Hiller JE, Mishra GD, Goode AD, Jefford M, et al. Healthy Living after Cancer: dissemination and implementation study of a telephone-delivered lifestyle program. BMC Cancer. 2015;15:992.